Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches

Toxicology in Vitro

Volumn 27, Issue 5, 2013, Pages 1570-1577

  Coecke, Sandra ^a   Pelkonen, Olavi ^b   Leite, Sofia Batista ^a,c   Bernauer, Ulrike ^d   Bessems, Jos G M ^e   Bois, Frederic Y ^f   Gundert Remy, Ursula ^g   Loizou, George ^h   Testai, Emanuela ⁱ   Zaldívar, José Manuel ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b UNIVERSITY OF OULU   (Finland)

^c INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^d FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h HEALTH AND SAFETY LABORATORY   (United Kingdom)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

ADME; Alternative methods validation; In silico; In vitro; Physiologically based toxicokinetic modelling

Indexed keywords

ABSORPTION; ARTICLE; ARTIFICIAL MEMBRANE; BIOAVAILABILITY; BIOTRANSFORMATION; COMPUTER MODEL; CONCENTRATION RESPONSE; DOSE RESPONSE; EXCRETION; EXPOSURE; IN VITRO STUDY; IN VIVO STUDY; METABOLISM; MODEL; PHYSIOLOGICALLY BASED TOXICOKINETIC MODELLING; PREDICTION; RISK ASSESSMENT; SIMULATION; THRESHOLD OF TOXICOLOGICAL CONCERN; TISSUE DISTRIBUTION; TOXICITY TESTING; TOXICOKINETICS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; RISK ASSESSMENT;

ANIMALIA;

EID: 84877667917     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.06.012     Document Type: Article

References (66)

1. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K.E., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F.Y., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., Tahti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J.M. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 2011, 85:367-485.
2. Andersen M.E. Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett. 2003, 138:9-27.
3. Barton H.A., Andersen M.E. A model for pharmacokinetics and physiological feedback among hormones of the testicular-pituitary axis in adult male rats: a framework for evaluating effects of endocrine active compounds. Toxicol. Sci. 1998, 45:174-187.
4. Bessems, J.G.M., 2009. Opinion on the usefulness of in vitro data for human risk assessment. Suggestions for better use of non-testing approaches. Letter report 320016002/2009 RIVM. http://www.rivm.nl/bibliotheek/rapporten/320016002.pdf.
5. Blaauboer B.J. Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicol. Lett. 2001, 120:111-123.
6. Blaauboer B.J. The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern. Lab. Anim. 2002, 30(Suppl. 2):85-91.
7. Blaauboer B.J. Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment. Altern. Lab. Anim. 2003, 31:277-281.
8. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 2003, 138:161-171.
9. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health 2010, 13:242-252.
10. Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F.Y., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M.N., Lave T., Leahy D.E., Lennernas H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M. Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern. Lab. Anim. 2007, 35:661-671.
11. *2, affect phenytoin autoinduction of clearance and maintenance dose. J. Pharmacol. Exp. Ther. 2010, 332:599-611.
12. Chen Y., Liu L., Monshouwer M., Fretland A.J. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. Drug Metab. Dispos. 2011, 39:2085-2092.
13. Clewell R.A., Clewell H.J. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 2008, 50:129-143.
14. Clewell R.A., Kremer J.J., Williams C.C., Campbell J.L., Andersen M.E., Borghoff S.J. Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. Toxicol. Sci. 2008, 103:241-259.
15. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidig A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 2006, 34:49-84.
16. Coecke S., Blaauboer B.J., Elaut G., Freeman S., Freidig A., Gensmantel N., Hoet P., Kapoulas V.M., Ladstetter B., Langley G., Leahy D., Mannens G., Meneguz A., Monshouwer M., Nemery B., Pelkonen O., Pfaller W., Prieto P., Proctor N., Rogiers V., Rostami-Hodjegan A., Sabbioni E., Steiling W., van de Sandt J.J. Toxicokinetics and metabolism. Altern. Lab. Anim. 2005, 33(Suppl. 1):147-175.
17. Conolly R.B., Butterworth B.E. Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk. Toxicol. Letters. 1995, 82-83:901-906.
18. Darwich A.S., Neuhoff S., Jamei M., Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the " Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr. Drug Metab. 2010, 11:716-729.
19. DeJongh J., Blaauboer B.J. Simulation of toluene kinetics in the rat by a physiologically based pharmacokinetic model with application of biotransformation parameters derived independently in vitro and in vivo. Fundam. Appl. Toxicol. 1996, 32:260-268.
20. DeJongh J., Forsby A., Houston J.B., Beckman M., Combes R., Blaauboer B.J. An integrated approach to the prediction of systemic toxicity using computer-based biokinetic models and biological in vitro test methods: overview of a prevalidation study based on the ECITTS Project. Toxicol. In Vitro 1999, 13:549-554.
21. Faller L.D. Mechanistic studies of sodium pump. Arch. Biochem. Biophys. 2008, 476:12-21.
22. Georgopoulos P.G., Roy A., Gallo M.A. Reconstruction of short term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models. J. Expo. Anal. Environ. Epidemiol. 1994, 4:309-328.
23. Geraets, L., Bessems, .J.G.M., in preparation. Use of a TTC for exposure via skin and via inhalation: The need for internal TTC-values.
24. Gulden M., Morchel S., Seibert H. Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. Toxicol. In Vitro 2001, 15:233-243.
25. Hein S., Bur M., Schaefer U.F., Lehr C.M. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. Eur. J. Pharm. Biopharm. 2011, 77:132-138.
26. Heringa M.B., Schreurs R.H., Busser F., van der Saag P.T., van der Burg B., Hermens J.L. Toward more useful in vitro toxicity data with measured free concentrations. Environ. Sci. Technol. 2004, 38:6263-6270.
27. Horvath G., Mendes E.S., Schmid N., Schmid A., Conner G.E., Fregien N.L., Salathe M., Wanner A. Rapid nongenomic actions of inhaled corticosteroids on long-acting beta(2)-agonist transport in the airway. Pulm. Pharmacol. Ther. 2011, 24:654-659.
28. Jamei M., Dickinson G.L., Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokin. 2009, 24:53-75.
29. Jayaraman R., Pilla Reddy V., Pasha M.K., Wang H., Sangthongpitag K., Yeo P., Hu C.Y., Wu X., Xin L., Goh E., New L.S., Ethirajulu K. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab. Dispos. 2011, 39:2219-2232.
30. Johanson G., Jonsson F., Bois F. Development of new technique for risk assessment using physiologically based toxicokinetic models. Amer. J. Ind. Med. Suppl. 1999, 1:101-103.
31. Kramer N.I., Busser F.J., Oosterwijk M.T., Schirmer K., Escher B.I., Hermens J.L. Development of a partition-controlled dosing system for cell assays. Chem. Res. Toxicol. 2010, 23:1806-1814.
32. Kramer N.I., Hermens J.L., Schirmer K. The influence of modes of action and physicochemical properties of chemicals on the correlation between in vitro and acute fish toxicity data. Toxicol. In Vitro 2009, 23:1372-1379.
33. Kumar V., Schuck E.L., Pelletier R.D., Farah N., Condon K.B., Ye M., Rowbottom C., King B.M., Zhang Z.Y., Saxton P.L., Wong Y.N. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemother. Pharmacol. 2011, 69:229-237.
34. Lafond M., Bouza B., Eyrichine S., Bonnin E., Crost E.H., Geraert P.A., Giardina T., Ajandouz E.H. An integrative in vitro approach to analyse digestion of wheat polysaccharides and the effect of enzyme supplementation. Br. J. Nutr. 2011, 1-10.
35. Lehmann A.D., Daum N., Bur M., Lehr C.M., Gehr P., Rothen-Rutishauser B.M. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. Eur. J. Pharm. Biopharm. 2011, 77:398-406.
36. Liao K.H., Tan Y.M., Clewell H.J. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal. 2007, 27:1223-1236.
37. Lipscomb J.C., Meek M.E., Krishnan K., Kedderis G.L., Clewell H., Haber L. Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments. Toxicol. Mechanisms Methods 2004, 14:145-158.
38. Lipscomb J.C., Poet T.S. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Therap. 2008, 118:82-103.
39. Louisse J., de Jong E., van de Sandt J.J., Blaauboer B.J., Woutersen R.A., Piersma A.H., Rietjens I.M., Verwei M. The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol. Sci. 2010, 118:470-484.
40. Louisse J., Verwei M., Woutersen R.A., Blaauboer B.J., Rietjens I.M. Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation. Expert Opin. Drug Metab. Toxicol. 2011, 8:11-27.
41. Millage K.K., Bergman J., Asgharian B., McClellan G. A review of inhalability fraction models: discussion and recommendations. Inhal. Toxicol. 2010, 22:151-159.
42. Mitra P., Audus K., Williams G., Yazdanian M., Galinis D. A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption. J. Pharm. Sci. 2011, http://dx.doi.org/ 10.10021jps.22596.
43. Mosquin P.L., Licata A.C., Liu B., Sumner S.C., Okino M.S. Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple biomarkers. J. Expos. Sci. Environ. Epidemiol. 2009, 19:284-297.
44. Nossol C., Diesing A.K., Walk N., Faber-Zuschratter H., Hartig R., Post A., Kluess J., Rothkotter H.J., Kahlert S. Air-liquid interface cultures enhance the oxygen supply and trigger the structural and functional differentiation of intestinal porcine epithelial cells (IPEC). Histochem. Cell Biol. 2011, 136:103-115.
45. OECD, 2008. Detailed Review Paper on The use of metabolising systems for in vitro testing of endocrine disruptors. OECD Series on Testing and Assessment. OECD Publishing No. 97.
46. Palmgren J.J., Monkkonen J., Korjamo T., Hassinen A., Auriola S. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur. J. Pharm. Biopharm. 2006, 64:369-378.
47. Pelkonen O., Tolonen A., Rousu T., Tursas L., Turpeinen M., Hokkanen J., Uusitalo J., Bouvier d'Yvoire M., Coecke S. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis. Altex 2009, 26:214-222.
48. Peyret T., Krishnan K. QSARs for PBPK modelling of environmental contaminants. SAR and QSAR Environ. Res. 2011, 22:129-169.
49. Peyret T., Poulin P., Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol. Appl. Pharmacol. 2010, 249:197-207.
50. Punt A., Schiffelers M.J., Jean Horbach G., van de Sandt J.J., Groothuis G.M., Rietjens I.M., Blaauboer B.J. Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. Regul. Toxicol. Pharmacol. 2011, 61:105-114.
51. Rostami-Hodjegan A., Lennard M.S., Tucker G.T., Ledger W.L. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertility Sterility 2004, 81:1187-1193.
52. Rostami-Hodjegan A., Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. 2007, 6:140-148.
53. Rostami A.A. Computational modeling of aerosol deposition in respiratory tract: a review. Inhal. Toxicol. 2009, 21:262-290.
54. Roy A., Georgopoulos P.G. Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models. J. Expos. Anal. Environ. Epidemiol. 1998, 8:407-422.
55. Seibert H., Morchel S., Gulden M. Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicol. In Vitro 2002, 16:289-297.
56. Svoboda M., Riha J., Wlcek K., Jaeger W., Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr. Drug Metab. 2011, 12:139-153.
57. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev. 2011, 64:508-514.
58. Tan Y.M., Liao K.H., Clewell H.J. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expos. Sci. Environ. Epidemiol. 2007, 17:591-603.
59. Tan Y.M., Liao K.H., Conolly R.B., Blount B.C., Mason A.M., Clewell H.J. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J. Toxicol. Environ. Health A 2006, 69:1727-1756.
60. Tanneberger K., Rico-Rico A., Kramer N.I., Busser F.J., Hermens J.L., Schirmer K. Effects of solvents and dosing procedure on chemical toxicity in cell-based in vitro assays. Environ. Sci. Technol. 2010, 44:4775-4781.
61. Tonnellier A., Coecke S., Zaldívar J.M. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. 2012, 86:393-403.
62. Turco L., Catone T., Caloni F., Di Consiglio E., Testai E., Stammati A. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human?. Toxicol. In Vitro 2011, 25:13-20.
63. van der Merwe D., Brooks J.D., Gehring R., Baynes R.E., Monteiro-Riviere N.A., Riviere J.E. A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicol. Sci. 2006, 89:188-204.
64. Vasdev N., Dorff P.N., O'Neil J.P., Chin F.T., Hanrahan S., VanBrocklin H.F. Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes. Bioorg. Med. Chem. 2011, 19:2959-2965.
65. Wang Z., Lee B., Pearce D., Qian S., Wang Y., Zhang Q., Chow M.S. Meclizine metabolism and pharmacokinetics: formulation on its absorption. J. Clin. Pharmacol 2011, September 8 [Epub ahead of print]. PMID: 21903894.
66. Willmann S., Hohn K., Edginton A., Sevestre M., Solodenko J., Weiss W., Lippert J., Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 2007, 34:401-431.